The text starts here.

News Release

FOR IMMEDIATE RELEASE
January 7, 2004

Eisai Inc., a U.S. Subsidiary of Eisai Co., Ltd., Assumes
All Distribution Responsibilities for ACIPHEX (R)

Eisai Inc., a U.S. Subsidiary of Eisai Co., Ltd., Assumes
All Distribution Responsibilities for ACIPHEX (R)


Eisai Inc. (Headquarters: New Jersey, Chairman: Soichi Matsuno), a U.S. subsidiary of Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito), has assumed the U.S. distribution responsibilities for ACIPHEX (R), a proton pump inhibitor, from Janssen Pharmaceutica, Inc. affiliate JOM Pharmaceutical Services. Effective December 29, 2003, Eisai Inc. began fulfilling purchase orders for ACIPHEX (R) from a distribution center in Memphis, Tennessee. Eisai and Janssen continue to co-promote ACIPHEX (R).


Eisai Inc. has rapidly grown its capabilities from research and development to manufacture, sales, and promotion. By building this distribution capability, the company's seamless structure for its products has been reinforced. Eisai Inc. has been operating the U.S. distribution of ARICEPT (R), its treatment for mild to moderate Alzheimer's disease.


ACIPHEX / PARIET (R), classified as a proton pump inhibitor, demonstrates strong proton pump inhibition at the final stage of acid secretion by preventing the function of the enzyme responsible for stomach acid production. ACIPHEX / PARIET (R) is now available in 70 countries worldwide. Eisai markets ACIPHEX / PARIET (R) through co-promotion with Janssen in the United States, the United Kingdom, Germany, Spain, China and Korea.


Contacts:

Eisai Co., Ltd.
Public Relations Department
+81-3-3817-5120